COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER IN JAPAN

被引：0
|
作者：
Morimoto, K. [1 ]
Moriwaki, K. [2 ]
Shimozuma, K. [3 ]
Nakayama, T. [1 ]
机构：
[1] Kyoto Univ, Kyoto, Japan
[2] Ritsumeikan Univ, Kyoto 26, Japan
[3] Ritsumeikan Univ, Kusatsu, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA7
引用
收藏
页码：S505 / S505
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US
    Luo, Xianmei
    Cai, Tingting
    Wu, Jinyan
    Li, Xingyu
    Wang, Xiaofan
    Ma, Haiying
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [42] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [43] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
  • [44] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China
    Zheng, Zhiwei
    Song, Xiaobing
    Qiu, Guodong
    Xu, Siqi
    Cai, Hongfu
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (03) : 433 - 440
  • [45] Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis
    Kaveh, Sara
    Ghadimi, Nashmil
    Alvar, Amirhossein Zarei
    Roudini, Kamran
    Daroudi, Rajabali
    HEALTH ECONOMICS REVIEW, 2024, 14 (01):
  • [46] Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    Wu, Haijun
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [47] COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA
    Tibet, B.
    VALUE IN HEALTH, 2018, 21 : S45 - S45
  • [48] A real world retrospective study of advanced gastric cancer patients treated with nivolumab plus chemotherapy
    Komoda, M.
    Okumura, Y.
    Arimizu, K.
    Matsumura, T.
    Nishijima, T.
    Esaki, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1370 - S1370
  • [49] Focusing on clinical trial ineligibility: Nivolumab plus chemotherapy for patients with advanced gastric cancer.
    Motoo, Iori
    Ando, Takayuki
    Nakayama, Yurika
    Ueda, Yuko
    Kajiura, Shinya
    Ogawa, Kohei
    Takagi, Hiroaki
    Tsukada, Kenichiro
    Tabata, Kazuhisa
    Ohya, Yuno
    Tamura, Hotaka
    Hosokawa, Ayumu
    Yasuda, Ichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 355 - 355
  • [50] Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
    Zhang, Mengdie
    Xu, Kai
    Lin, Yingtao
    Zhou, Chongchong
    Bao, Yuwen
    Zhang, Lingli
    Li, Xin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345